Motif Neurotech, a company commercializing technology based on research at Rice University, has received approval from the U.S. Food and Drug Administration to begin the first clinical trial of its therapeutic brain-computer interface (BCI) for treatment of treatment-resistant depression.
The decision is a significant step supporting Motif’s mission to serve the nearly 3 million Americans living with the condition.
The early feasibility study will test Motif’s BCI technology, a small, wirelessly powered implantable device designed to deliver electrical stimulation to brain circuits linked to depression. [Read more…] about Brain-computer interface based on Rice research wins FDA approval for first clinical trial